Risk of Heart Failure Decompensation After Stopping Entresto
Yes, your patient can absolutely experience heart failure decompensation within 15 days of stopping Entresto, and this risk is clinically significant. The most compelling evidence shows that discontinuing sacubitril/valsartan leads to deterioration of left ventricular ejection fraction and worsening functional class despite resuming standard therapy with ACE inhibitors or ARBs 1.
Evidence for Rapid Deterioration
A 2021 study specifically examined what happens when patients discontinue Entresto after 5-6 months of treatment. Patients who stopped sacubitril/valsartan and were shifted back to ACE inhibitors or ARBs experienced:
- Worsening of NYHA functional class compared to their status while on Entresto (p=0.001) 1
- Deterioration of left ventricular ejection fraction despite being compliant with optimal conventional therapy (p=0.001) 1
- Increased end-diastolic volume, indicating worsening cardiac remodeling (p=0.001) 1
The critical finding is that this deterioration occurred despite patients being compliant with evidence-based ACE inhibitor or ARB therapy, meaning the loss of Entresto's benefits cannot be fully compensated by reverting to standard RAAS blockade 1.
Mechanism of Risk
The FDA label for sacubitril/valsartan warns about several mechanisms that could precipitate decompensation:
- Hypotension occurs in 18% of patients on Entresto 2
- Renal dysfunction affects approximately 5% of patients 2
- Hyperkalemia occurs in 12% of patients 2
When Entresto is stopped, the sudden loss of dual neprilysin inhibition and angiotensin receptor blockade can lead to:
- Reduced natriuretic peptide activity
- Increased vasoconstriction
- Fluid retention
- Worsening cardiac remodeling
Critical Management Considerations
If you must stop Entresto, you should:
- Immediately substitute with an ACE inhibitor or ARB to maintain RAAS blockade, though this will not fully prevent deterioration 1
- Observe a 36-hour washout period before starting an ACE inhibitor to avoid angioedema risk 2
- Increase monitoring frequency with daily weights, checking for signs of congestion 3
- Optimize diuretic dosing proactively, as patients should increase furosemide if weight increases persistently (>2 days) by >1.5-2.0 kg 3
- Continue carvedilol without interruption, as beta-blockers should never be stopped abruptly due to risk of rebound myocardial ischemia, infarction, and arrhythmias 3
Timeline Considerations
While the study demonstrating deterioration examined patients at 6 and 12 months 1, the physiologic changes begin immediately:
- Sacubitril/valsartan has a half-life allowing twice-daily dosing 2
- Neurohormonal activation can occur within days of stopping RAAS blockade
- Clinical decompensation within 15 days is physiologically plausible and should be anticipated
Common Pitfalls to Avoid
Do not assume that resuming an ACE inhibitor or ARB will maintain the patient's current stability. The evidence clearly shows that patients deteriorate despite optimal conventional therapy after stopping Entresto 1.
Do not stop the beta-blocker (carvedilol) during this transition. European Society of Cardiology guidelines emphasize that beta-blockers should not be stopped suddenly unless absolutely necessary, as there is significant risk of rebound cardiovascular events 3.
Do not wait for symptoms to appear before intensifying monitoring. Proactive daily weight monitoring and preemptive diuretic adjustment are essential 3.
Alternative Approach
If the reason for stopping Entresto is cost or tolerability rather than absolute necessity, strongly reconsider this decision. Sacubitril/valsartan demonstrates consistent benefits in reducing prognostic biomarkers, improving health status, and reversing cardiac remodeling regardless of heart failure duration 4. The medication reduces cardiovascular death and heart failure hospitalization more effectively than ACE inhibitors 5.
If discontinuation is unavoidable due to adverse effects (hypotension, renal dysfunction, hyperkalemia), address the specific adverse effect rather than stopping the medication entirely 2.